RTTNews | Aug 10, 2021 10:15AM EDT

10:14 Tuesday, August 10, 2021 (RTTNews.com) - Arcturus Therapeutics Holdings Inc. (ARCT) shares are rising more than 27 percent on Tuesday morning trade after the company announced the selection of its ARCT-021 by a global entity to include in phase 3 vaccine trial and an agreement with Vinbiocare in Vietnam to manufacture its investigational COVID-19 vaccines. The company reported a wider net loss for the second quarter.

The phase 3 study will evaluate a 5-mcg dose of ARCT-021 administered as a single injection regimen.

Further, the company announced an agreement with Vinbiocare to fund and establish a facility in Vietnam for the manufacture of Arcturus' investigational COVID-19 vaccines. On an upfront payment of $40 million, Vinbiocare will purchase the mRNA drug substance from Arcturus and pay a royalty on manufactured doses.

Currently, shares are at $62.47, up 29.49 percent from the previous close of $48.24 on a volume of 1,527,424. For the 52-week period, the shares have traded in a range of $24.87-$129.71 on average volume of 737,026.

Read the original article on RTTNews ( https://www.rttnews.com/3217736/arcturus-therapeutics-up-29-after-inclusion-of-arct-021-in-phase-3-covid-19-vaccine-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved